Sanofi witnesses faster profit growth on Dupixent, flu vaccine | The Financial Express

Sanofi witnesses faster profit growth on Dupixent, flu vaccine

Reportedly, revenue from exzema and asthma drug Dupixent, jointly developed with Regeneron, jumped by a currency-adjusted 44.5% to 2.3 billion euros in the quarter, soundly beating an analyst consensus of 2.1 billion euros.

Sanofi witnesses faster profit growth on Dupixent, flu vaccine
A logo on the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France June 15, 2022. (Image Credits: Reuters)

French drugmaker Sanofi on Friday predicted faster earnings growth this year on strong demand for its bestselling drug Dupixent and for its flu vaccines.

According to a report by news agency Reuters, Sanofi said in a statement that it now expects 2022 adjusted earnings per share to grow by about 16 percent, not taking into account an expected positive currency impact of between 9.5 percent and 10.5 percent. It had previously forecast growth of percent.

Sanofi reported a 26.5 percent rise in third-quarter business operating income, or adjusted earnings before interest and tax, to 4.5 billion euros ($4.49 billion), well ahead of an average analyst estimate of 4.17 billion euros.

Sanofi shares plunged in August after disappointing trial results of a once-promising breast cancer drug candidate heightened concerns about the company’s development pipeline and investors also fretted over legal claims that the heartburn drug Zantac caused cancer.

The shares have not recovered much and Credit Suisse analysts have said Sanofi is trading about one-third below its European peers, relative to estimated 2023 earnings.

Finance chief Jean-Baptiste de Chatillon, who has described the discount as grossly overdone, said on Friday that Sanofi would follow through on its strategy.

“We know we have some headwinds and we are there to fight them and to demonstrate to our shareholders that we can create more value,” he told journalists in a call as quoted by Reuters.

Reportedly, revenue from exzema and asthma drug Dupixent, jointly developed with Regeneron, jumped by a currency-adjusted 44.5% to 2.3 billion euros in the quarter, soundly beating an analyst consensus of 2.1 billion euros.

The company is pursuing further growth for Dupixent in inflammatory skin conditions and smoker’s lung, where keenly awaited trial data is expected in the first half of 2023.

Sales from influenza vaccines jumped by a currency-adjusted 32.4% to 2 billion euros, surpassing an analyst consensus of 1.6 billion euros, on swift uptake of a more expensive new high-dose shot.

CFO de Chatillon said the company also benefited during the quarter from bringing forward the seasonal production ramp-up and distribution but added that overall appetite in the U.S. population for flu shots was low. A strong U.S. dollar also boosted the value of overseas group revenues.

(With inputs from Reuters)

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

First published on: 28-10-2022 at 14:06 IST